Incannex Healthcare announces that is has appointed Quest Pharmaceutical Services, QPS, to provide regulatory advice and manage clinical trials for the development of CannQuit and ReneCann products for addiction and immune-disordered skin diseases. QPS is currently drafting pre-investigational new drug submissions for both the European Union’s European Medicines Agency and the US Food and Drug Administration for the CannQuit and ReneCann Products. CEO and Managing Director, Joel Latham said; "QPS is a perfect fit for us to develop these products across the globe. Not only will QPS assist us with conducting clinical research, it has been engaged to advise upon the quickest route to commercialising the products in different regulatory jurisdictions."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IXHL:
- Incannex Appoints QPS to Advance CannQuit-N™ (Nicotine), CannQuit-O™ (Opioid) and Renecann™ Products in the USA and EU
- Incannex to Commercialise its Psychedelic Clinics Business in Collaborative Partnership with Leading Psychedelic Experts
- Incannex to commercialize psychedelic clinics business
- Incannex announces results of interim review on Phase 2 program for GAD
- Interim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatment